National News

Positive discrimination

NPA News - 4 hours 1 min ago
Most of us can agree that treating somebody unfairly on the basis of their sex, race or disability isn’t acceptable – but is it ever justified for employers to prioritise marginalised groups? No matter your personal view point, the law makes a clear distinction between positive discrimination and positive action. In short, treating one person more favourably than another because they have a protected characteristic is generally prohibited under the Equality Act (EqA) 2010, unless it relates to a genuine occupational requirement. What you can do: Positive action Under the EqA, employers are permitted to take positive action in situations where a group of people with a shared protected characteristic (such as gender, race or disability) are disadvantaged or under-represented in connection to that characteristic. In other words, in cases where there is a clear imbalance of opportunity, employers can take proportionate measures to address the disadvantage and encourage participation without leaving themselves exposed to discrimination claims. As of April 2011, positive action can also be exercised within recruitment and promotion in cases where the employer reasonably believes that there is a lack of representation. This allows an employer, when making hiring decisions, to select a candidate from a group that is disadvantaged or under-represented in its workforce if the candidates are of equal merit.…
Categories: National News

Class 2 Medicines recall: Ranitidine 75mg Tablets (Various Liveries)

PSNC News - 6 hours 41 min ago

Drug alert number: EL (19)A/37

Date issued: 21 November 2019

OTC Concepts Ltd, Relconchem Ltd and Noumed Life Sciences Ltd are recalling all unexpired batches of the products listed below from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic
potential.

OTC Concepts Ltd

Product PL Number Ranitidine 75mg Tablets 20338/0020

Relonchem Limited

Product PL Number Relonchem Ranitidine 75mg Tablets (6) 20395/0079 Relonchem Ranitidine 75mg Tablets (12) 20395/0079 Bells Healthcare Ranitidine 75mg Tablets (12) 20395/0079 Numark Ranitidine 75mg Film Coated Tablets (12) 20395/0079 Tesco Heartburn and Indigestion Relief 75mg Film Coated Tablets (12) 20395/0079

Noumed Life Sciences Ltd

Product PL Number Noumed Indigestion Relief 75mg Film-Coated Tablets 44041/0027 Gavilast Heartburn and Indigestion 75mg FilmCoated Tablets 44041/0028 Ranitidine 75mg Film-Coated Tablets 44041/0028

 

Medreich Plc are recalling specific batches of the products listed below from pharmacies and retail stores as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

Medreich Plc

ASDA Ranitidine 75 mg Tablets (12) PL 21880/0022 Batch Number Expiry Date Pack Size First Distributed 370190 31/01/2020 1 x 12 August 2017

 

Peach Ethical Indigestion Relief Ranitidine 75mg Film Coated Tablets (12)
PL 21880/0022 Batch Number Expiry Date Pack Size First Distributed 370049 31/12/2019 1 x 12 October 2017

 

Sainsbury’s Indigestion Relief Tablets (12) PL 21880/0022 Batch Number Expiry Date Pack Size First Distributed 370065 31/12/2019 1 x 12 May 2017 370066 31/12/2019 1 x 12 May 2017

 

Tesco Indigestion Relief Ranitidine 75mg film coated tablets
PL 21880/0022 Batch Number Expiry Date Pack Size First Distributed 370050 31/12/2019 1 x 12 March 2017 370051 31/12/2019 1 x 12 March 2017 370052 31/12/2019 1 x 12 April 2017 370064 31/12/2019 1 x 12 May 2017

Advice for healthcare professionals and retail stores
• Stop supplying the above products immediately and remove from shelves in your store. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
• If you receive queries about this issue from patients, advise them to contact their GP, pharmacist or healthcare professional to review ongoing treatment.

This is an on-going issue and the MHRA is actively involved with the European Medicines Agency and with other medicines regulators to determine any possible impact. An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses.

View the full Drug Alert here.

Company contacts for further information

OTC Concepts Limited
• For stock control enquiries please contact Customer Service team on +44 (0) 1484 665733 or Warehouse@dalkeithlabs.co.uk
• For medical information enquiries please contact Pharmacovigilance Department on +44 (0) 1525 292344 or RanitidinePV@dalkeithlabs.co.uk

Relonchem Limited
• For stock control enquiries please contact Relonchem Customer Service team on +44 (0) 151 422 1200 or sales@relonchem.com
• For medical information enquiries please contact Relonchem Pharmacovigilance Department on +44 (0) 151 556 1857 or medicalinformation@relonchem.com

Noumed Life Sciences Limited
• For stock control enquiries please contact Noumed Life Sciences Limited Customer Service team on +44 (0) 2033998900 or nicole.mascowe@noumed.co.uk
• For medical information enquiries please contact Noumed Life Sciences Limited Pharmacovigilance Department on Tel +44 (0) 2033998960 or akhtarhms@skayedzan.co.uk

Medreich PLC
• For stock control enquiries please contact Medreich Plc. Customer Service team on +44 (0) 20 8831 1580 or cs_team@medreich.co.uk
• For medical information enquiries please contact Medreich Plc. Pharmacovigilance Department on +44 (0) 20 8831 1580 or qagroup@medreich.co.uk

Categories: National News

Distance selling pharmacies – updating NHS website gateway criterion

NPA News - 7 hours 32 min ago
Distance selling pharmacies (DSPs) are encouraged to ensure they complete and submit the updated spreadsheet produced by the NHS Business Services Authority (NHSBSA) for the collation of information required to meet the Pharmacy Quality Scheme (PQS) NHS website gateway criterion. Unlike non-DSP contractors, DSPs do not have full NHS website entries on the NHS website. Therefore, the following information will be required from DSPs to populate their profiles: Trading name of the pharmacy on the NHS website Telephone number and website URL Opening hours for the pharmacy (including Easter Sunday and public and bank holiday opening hours for 2019/20) Services provided by the pharmacy — this must include New Medicine Service (NMS) and/or the NHS Community Pharmacy seasonal influenza vaccination Advanced Service Facilities available (for example, consultation rooms) A spreadsheet to collect the information is available on the NHSBSA website or in Annex 1 in the NHS England and NHS Improvement (NHSE&I) guidance. All three sections must be completed and sent between 00.00am on 1 October 2019 and 11:59pm on 30 November 2019 via email to the NHSBSA Provider Assurance Team (nhsbsa.pharmacysupport@nhs.net) The email subject line must state “PQS FEB REVIEW” followed by the pharmacy ODS code; failure to include this information will result in no record of the email being made in the summary report of DSPs contractors that have achieved this gateway criterion.…
Categories: National News

Class 2 pharmacy level medicines recall – Action within 48 hours – Ranitidine tablets 75mg

NPA News - 7 hours 57 min ago
DRUG ALERT Class 2 pharmacy level medicines recall – Action within 48 hours – Ranitidine tablets 75mg (EL(19)A/37) Ref: EL(19)A/37 21 November 2019 Ranitidine tablets 75mg (Manufactured by various manufacturers) Various PL numbers A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for various brands, product licence (PL) numbers and batches of ranitidine tablets 75mg. Further details on the affected brands, batch numbers and PL numbers can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy Services team November 2019.  …
Categories: National News

Have you signed up for priority access to utilities?

PSNC News - 8 hours 5 min ago

Community pharmacy contractors confirm each year that business continuity arrangements are in place via their information governance toolkit declarations (now known as the Data Security and Protection toolkit). You can now sign up for the Priority Services Register to boost your business continuity arrangements further. Inclusion on this register should mean your pharmacy has priority access to electricity, water and gas supplies.

The Priority Services Register is run by the UK’s utility companies.

How to sign-up?

Your utility bills may explain how to sign-up and provide contact details. Alternatively, identify who your energy supplier is at the Energy Networks Association’s (ENA’s) website or search for “PSR” and or “Priority Service Register” on your utility company websites.

Whilst signing up, tick the information-sharing box to confirm your details can be shared between utility companies for PSR purposes.

When requesting priority (usually via an online form):

  • enter two or more contacts;
  • confirm your email address for receiving messages about planned or unexpected service;
  • select the reasoning for your priority, including if these options provided: medical equipment->refrigerated medicines; and chronic/serious illness; and
  • include the words ‘pharmacy’ within your request.

You will need to send a separate request to your water supply company explaining you are a ‘sensitive property’, as relevant data sharing between water and other utility companies is not yet in place.

 

Categories: National News

SSP for fluoxetine capsules 30mg – extended and amended

NPA News - 20 November 2019 - 4:56pm
The Serious Shortage Protocol (SSP) for fluoxetine capsules in the 30mg strength, previously due to end on 31 October 2019, is being extended with an amended end date of 18 December 2019. The SSP has also been changed as follows: Pharmacists should supply fluoxetine capsules 10mg instead of tablets; that is 1 x fluoxetine capsule 10mg and 1 x fluoxetine capsule 20mg Previously pharmacists  were directed to supply 1 x fluoxetine tablet 10mg in addition to 1 x fluoxetine capsule 20mg The SSP for fluoxetine capsules in the 30mg strength, introduced on 3 October 2019, allows pharmacists to switch to an alternative available strength of fluoxetine. The SSP for fluoxetine capsules 10mg was withdrawn on 25 October 2019. The SSP for fluoxetine capsules 40mg was withdrawn on 20 November 2019. Further information on the SSPs for fluoxetine is available on the NHS Business Services Authority website.…
Categories: National News

Contractor Notice: Further extension and amendment to SSP02 only

PSNC News - 20 November 2019 - 4:10pm

The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Fluoxetine capsules.

The SSP for Fluoxetine 30mg capsules has been extended with a change to an alternative product (please check updated SSP02 protocol before dispensing), whilst the SSP for Fluoxetine 40mg capsules expired 20th November 2019.

SSP02 for Fluoxetine 30mg capsules

This has been further extended with a revised expiry date now set as 18th December 2019.

An amendment to the SSP also means that pharmacists who decide it is appropriate to follow the protocol must now supply Fluoxetine 10mg capsules instead of tablets – i.e. for every Fluoxetine 30mg capsule supply: 1 x Fluoxetine 10mg capsule, plus 1 x Fluoxetine 20mg capsule.

SSP03 for Fluoxetine 40mg capsules

SSP03 has now expired effective 20 November 2019 as sufficient stock is now available to supply normal demand for dispensing against prescriptions for Fluoxetine 40mg capsules. SSP03 is therefore no longer valid for use and any prescriptions presented for Fluoxetine 40mg must be dispensed in accordance with the original prescription.

Summary SSP & Product Current expiry date Notes SSP02: Fluoxetine 30mg capsules This SSP has been varied – the revised end date is now 18th December 2019

New directions state the pharmacist must now supply Fluoxetine 10mg capsules plus Fluoxetine 20mg capsules

(This SSP previously stated that Fluoxetine 10mg tablets plus Fluoxetine 20mg capsules must be provided.) SSP03: Fluoxetine 40mg capsules This SSP expired 20th November 2019 SSP01: Fluoxetine 10mg capsules This SSP expired 25th October 2019 Top Tips

  • View our SSP submission reminder to ensure your SSP claims are appropriately submitted to NHSBSA  for reimbursement.
  • Ensure that the dispensed notification messages for all EPS SSP claims are submitted before midnight on the 20th November.
  • Pharmacy teams are advised to submit SSP claims using the EPS token if your PMR systems do not support/capture all the SSP endorsement requirements for a valid claim.
  • If using a token to submit SSP claims, to avoid double-claiming, remember to mark the item covered by the SSP as ‘Not Dispensed’/’ND’ on the EPS message.
  • Where available, use the claim amend facility on your PMR system to rectify any incorrect EPS claims already submitted this month.
  • Any paper prescriptions or tokens with SSP claims need to be placed in a red separator (and kept separate from other tokens for non-payment i.e. with paid/exempt status).
  • Check that the correct number of patient charges are collected and declared on the end of month FP34C submission form.
  • SSPs will be accepted for up to three calendar months after expiry or withdrawal of the SSP. For example, for the Fluoxetine 30mg capsules SSP, which was withdrawn on 20th November, the NHSBSA would look for the “NCSO” endorsement in the November batch (submitted by the 5th of December), December batch (submitted by the 5th January) and January batch (submitted by the 5th of February).
  • NHSBSAs advise that contractor SSP claims should be clear and unambiguous and follow the protocol guidelines – NHSBSA processing staff must be able to determine what has been supplied.
FAQ

Q. Can I supply Fluoxetine 10mg tablets and Fluoxetine 20mg capsules for SSP02 (Fluoxetine 30mg capsules) after 20th November 2019?

A. No. SSP02 was amended so that after 20th November, contractors will only be able to supply a combination of 1 x Fluoxetine 10mg capsules and 1 x Fluoxetine 20mg capsules. Fluoxetine 10mg tablets can no longer be supplied against SSP02 after the 20th November. Before issuing an SSP check the up-to date SSP protocol here.

Additional information

On 3rd October 2019 it was announced that the Secretary of State had authorised three Serious Shortage Protocols (SSPs) to help manage the supply of some formulations of Fluoxetine. These SSPs were put in place to manage stock and to try to ensure that fewer patients have to return to their prescriber.

View PSNC’s support guidance to endorsing Fluoxetine SSPs here.

View PSNC’s SSP FAQ page here.

View NHSBSA’s support guidance to endorsing Fluoxetine SSPs here.

To view the latest SSP updates visit: www.nhsbsa.nhs.uk/pharmacies-gp-practices-andappliance-contractors/serious-shortage-protocols-ssps

Categories: National News

England: Pharmacy Quality Scheme (PQS) – Primary Care Networks (PCN) engagement guidance, plus NHS website and DoS profile reminder

NPA News - 20 November 2019 - 11:58am
This update provides information on Primary Care Networks (PCNs) and lists actions required by community pharmacy contractors to meet the requirements of this domain under the Pharmacy Quality Scheme (PQS). A key domain of the PQS covers PCNs to prepare pharmacies for engagement with PCNs and the role that they can play within PCNs.  The aim is to encourage community pharmacies to engage and work effectively in collaboration with PCNs. Under the PCN domain, community pharmacies are required: Have a named lead representative appointed for all community pharmacies within the PCN footprint; and Pharmacies claiming for this domain must submit the name of the appointed PCN lead, pharmacy name and ODS code for the pharmacy PCN lead Value Meeting the requirements of this domain will earn the pharmacy the following: PCN lead — 22.5 points valued of at least £1,440 to a maximum of £2,880 Non-PCN lead — 12.5 points valued of at least £800 to a maximum of £1,600 PCNs are expected to be an integral part of the NHS structure in the future. The role of the Pharmacy PCN lead and community pharmacy’s engagement with PCNs will extend beyond this year’s PQS, although we currently have no visibility how this will be reimbursed thereafter.…
Categories: National News

Regulations Officer job opportunity at PSNC

PSNC News - 20 November 2019 - 11:32am

PSNC is seeking a new recruit to support its legislative and regulatory affairs work.

The appointee – Regulations Officer – will work closely with PSNC’s Director of Operations and Support, to provide guidance to pharmacy contractors and LPCs on the ‘terms of service’, market entry regulations, data protection issues and other legislative and regulatory matters affecting the provision of NHS community pharmacy services; support the work of other PSNC teams; and assist internal governance, including PSNC elections for ‘Independent’ pharmacy representatives.

This role would suit candidates with some legal and/or pharmacy, education or experience.

Employment type: Full-time (Monday to Friday, 35 hours per week)

Location: Farringdon, London

Salary: will be in the range of £28k – £30k pa.

Job description and person specification

Applicants should email a CV and covering letter to jobs@psnc.org.uk with ‘Application for Regulations Officer position’ in the subject line of the email.

The closing date for applications is 8th December 2019. The application process may close earlier than the initial closing date if high volumes of applications are received.

Interviews will be conducted on Monday 16th December 2019.

No recruitment agencies please.

Categories: National News

NPA medication safety update (MSO report) Quarter 3 2019 (England)

NPA News - 19 November 2019 - 5:16pm
The NPA is pleased to publish its third medication safety update / Medication Safety Officer’s (MSO) report on patient safety incidents covering the third quarter of 2019 (Q3). The full update can be accessed here. NPA’s MSO role The NPA holds the role of Medication Safety officer (MSO) for all independent community pharmacies in England with fewer than 50 branches. The NPA’s MSO role was established when the Medicines and Healthcare product Regulatory Agency (MHRA) Stage Three: Directive Improving medication error incident reporting and learning alert (NHS/PSA/D/2014/005) was issued in March 2014, and has continued since. If you operate an independent community pharmacy, and there are fewer than 50 branches in your pharmacy chain, then the NPA is your MSO. Jasmine Shah, NPA Head of Advice and Support Services, currently holds the role of MSO at the NPA. As part of this role, we are working together with the wider pharmacy sector on the patient safety agenda, and in particular we look forward to playing our full part in the work of the sector-wide Patient Safety Group. New style report This MSO report improves upon the previous publications and covers current hot topics in patient safety including the Pharmacy Quality Scheme (PQS), a focus on insulin and valproate, isotretinoin, sepsis, supplying medicines online, and the introduction of Real Time Exemption Checking (RTEC).…
Categories: National News

Price Concessions – November 2019

NPA News - 19 November 2019 - 4:45pm
Drug (pack size) Price concession Alverine capsules 60mg (100) £9.25 Cefalexin oral suspension 125mg/5ml (100ml) £1.95 Cefalexin oral suspension 250mg/5ml (100ml) £2.25 Cyclizine solution for injection ampoules 50mg/1ml (5) £12.56 Hydroxyzine tablets 25mg (28) £1.02 Lamotrigine dispersible tablets sugar free 100mg (56) £9.99 Meloxicam tablets 7.5mg (30) £1.91 Orlistat capsules 120mg (84) £28.49 Venlafaxine tablets 75mg (56) £4.96  …
Categories: National News

November 2019 Price Concessions – 1st update

PSNC News - 19 November 2019 - 3:00pm

Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions:

Drug Pack size Price Concession Alverine 60mg capsules 100 £9.25 Cefalexin 125mg/5ml oral suspension 100ml £1.95 Cefalexin 250mg/5ml oral suspension 100ml £2.25 Cyclizine 50mg/1ml solution for injection ampoules 5 £12.56 Hydroxyzine 25mg tablets 28 £1.02 Lamotrigine 100mg dispersible tablets sugar free 56 £9.99 Meloxicam 7.5mg tablets 30 £1.91 Orlistat 120mg capsules 84 £28.49 Venlafaxine 75mg tablets 56 £4.96

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

PSNC is still working with the DHSC to agree further concessionary prices on other drugs reported to be unavailable at the stated November 2019 Drug Tariff price. Contractors will be alerted to further updates to the price concession list through our website and via our e-news email.  If you wish to subscribe to our email list, you can receive an email as soon as any announcements are made. Please note that PSNC cannot provide details of any generic products awaiting price concession approval from DHSC.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Categories: National News

Class 2 pharmacy level medicines recall – Action within 48 hours – ranitidine products

NPA News - 19 November 2019 - 1:04pm
DRUG ALERT Class 2 medicines recall – Action within 48 hours – Ranitidine products (Creo Pharma Limited (Zentiva Pharma UK Ltd) and Tillomed Laboratories Limited) Ref: EL (19)A/36 19 November 2019 Ranitidine oral solution 30mg/1ml – PL 31862/0023 (Manufactured by Creo Pharma Limited (Zentiva Pharma UK Ltd) Ranitidine tablets 150mg – PL 11311/0138 (Manufactured by Tillomed Laboratories Limited) A Class 2 medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for two ranitidine products. – this is a pharmacy level recall alert which requires action within 48 hours of the alert being issued on 19 November 2019: Creo Pharma Limited (Zentiva Pharma UK Ltd) and Tillomed Laboratories Limited are recalling all unexpired stock of the above preparations from pharmacies due to potential contamination of ranitidine with N-nitrosodimethylamine (NDMA) as an impurity — this is a precautionary measure as NDMA has genotoxic and carcinogenic potential. Advice for healthcare professionals, including pharmacy teams Pharmacists and pharmacy teams are required to: Stop supplying the affected products immediately Quarantine all remaining stock and return it to the supplier using their agreed process Provide the following advice to patients making enquiries about the issue: Do not stop taking their medicines – stopping treatment can pose more of a health risk than the contaminant presents Patients do not need to see their doctor until their next routine appointment/treatment review Speak to their doctor if they have concerns Creo Pharma Limited (Zentiva Pharma UK Ltd) can be contacted as below: Stock control enquiries – contact the Customer Services team on 0844 8793 188 or GFD-CUSTOMERSERVICES@zentiva.com Medical information enquiries — contact the Medical Information team on 800 090 2408 or UKMedInfo@zentiva.com Tillomed Laboratories Limited can be contacted as below: For all enquires email qa@tillomed.co.uk Stock should be returned to following address: Mawdsley Brooks Redhouse Rockingham Way Adwick-le-Street Doncaster DN6 7FB Produced by the NPA Pharmacy Services team November 2019.…
Categories: National News

Campaigning for community pharmacy in the 2019 General Election

PSNC News - 19 November 2019 - 11:41am

The National Pharmacy Association (NPA), Royal Pharmaceutical Society (RPS) and Pharmaceutical Services Negotiating Committee (PSNC) have created resources to help promote community pharmacy ahead of the General Election on 12th December.

The upcoming election presents a great opportunity for the sector to be recognised as a valuable health and wellbeing asset, and a solution to many longstanding problems in the NHS. To help make these messages clear to all candidates standing in the election, the pharmacy organisations have created a shared ‘pharmacy manifesto’, which sets out how we hope any new Government will commit to investing in the sector.

This joint manifesto is available in our ‘General Election Hub’ and may be a useful document for any LPCs or contractors who are engaging with parliamentary candidates in the lead up to the 2019 General Election.

The ‘General Election Hub‘ also contains some additional guidance from PSNC for LPCs and contractors hosting pharmacy visits with candidates in the coming weeks. This includes some tips on content and key messages, as well as a template invitation and press release.

Categories: National News

Class 2 Medicines recall: Ranitidine Oral Solution 30mg/Ml (Creo Pharma Limited) and Ranitidine 150mg Tablets (Tillomed Laboratories Limited)

PSNC News - 19 November 2019 - 11:27am

Drug alert number: EL (19)A/36

Date issued: 19 November 2019

Creo Pharma Limited and Tillomed Laboratories Limited are recalling all unexpired stock of the ranitidine Oral Solution 30mg/Ml and ranitidine 150mg Tablets listed below from pharmacies as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

Creo Pharma Limited (Zentiva Pharma UK Ltd)

Product PL Number Ranitidine Oral Solution 30mg/ml 31862/0023

Tillomed Laboratories Limited

Product  PL Number Ranitidine 150mg Tablets 11311/0138

 

Advice for healthcare professionals and retail stores
• Stop supplying the above products immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
• If you receive queries about this issue from patients, advise them not to stop taking their medication as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment.

This is an on-going issue and the MHRA is actively involved with the European Medicines Agency and with other medicines regulators to determine any possible impact. An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses.

View the full Drug Alert here.

Creo Pharma Limited:

For stock control enquiries contact Zentiva Customer Service team: 0844 8793 188 or GFD-CUSTOMERSERVICES@zentiva.com
For medical information contact Zentiva medical information team: 0800 090 2408 or UKMedInfo@zentiva.com

Tillomed Laboratories Limited:

For enquiries please email Tillomed on qa@tillomed.co.uk.

All stock should be returned to following address:
Mawdsley Brooks
Redhouse
Rockingham Way
Adwick-le-Street
Doncaster, DN6 7FB

 

Categories: National News

EPS Phase 4 rollout begins with TPP SystmOne GP system

PSNC News - 18 November 2019 - 4:30pm

From today (18th November) EPS Phase 4 will begin rolling out to more GP practices using the TPP SystmOne GP system. All community pharmacy teams should therefore be aware that they may receive EPS Phase 4 tokens to process.

Full rollout for TPP SystmOne GP system practices will take place in the coming weeks and months on a location by location basis. Areas going live this year include parts of London, Gloucestershire and Greater Huddersfield.

Rollout dates for EMIS, Microtest and Vision GP practices will be finalised later. Specific dates will be made available on NHS Digital’s EPS Phase 4 deployment schedule webpage.

The start of the national rollout follows a successful pilot which tested the functionality in all four GP prescribing systems. The pilot began in November 2018 and involved 60 GP practices across England.

Under EPS Phase 4, patients can choose to take their token to any pharmacy in England. If you receive a Phase 4 token, simply scan the barcode and dispense it as you would any other electronic prescription.

As with all EPS prescriptions, dispense notifications and endorsements need to be added to the electronic prescription using your pharmacy system. Endorsements written or printed onto any type of EPS token will not be processed by the NHS Business Services Authority (NHSBSA).

Recommended actions

Refresh your EPS Phase 4 knowledge with PSNC’s top tips for processing Phase 4 prescriptions and learn more on our dedicated Phase 4 webpage.

 

 

Categories: National News

Class 3 medicines recall – Action within five days: Folic acid tablets 5mg (Accord UK Ltd)

NPA News - 18 November 2019 - 11:00am
DRUG ALERT Class 3 medicines recall – Action within five days: Folic acid tablets 5mg (Accord UK Ltd) Ref: EL (19)A/35 Date: 18 November 2019 Folic acid tablets 5mg (Manufactured by Accord UK Ltd) PL 0142/5522 A Class 3 wholesaler level medicines recall has been issued by the Medicines & Healthcare products Regulatory Agency (MHRA) for a specific batch number of Folic acid tablets 5mg manufactured by Accord UK Ltd. Further information can be found on the MHRA section on the GOV.UK website. Produced by the NPA Pharmacy Services team November 2019.  …
Categories: National News

Class 3 Medicines recall: Folic Acid tablets BP 5mg (Accord-UK Ltd)

PSNC News - 18 November 2019 - 10:49am

Class 3 Medicines recall: Folic Acid tablets BP 5mg (Accord-UK Ltd)

Drug alert number: EL (19)A/35

Date issued: 18 November 2019

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 3 medicines recall for:

Folic Acid tablets BP 5mg (Accord-UK Ltd)

Accord-UK Ltd has informed MHRA of an issue related to decommissioning of the above batch. Upon decommissioning at the pharmacy, there have been reports stating that when scanning the serialised 2D code, the status of packs may report as ‘EXPORT.’ Although there is no risk to product quality, any remaining stock should be quarantined and returned.

Folic Acid tablets BP 5mg – PL 0142/5522

Batch Number Expiry Date Pack Size First Distributed HU57 January 2021 28 26/03/2019

Advice for healthcare professionals

  • Stop supplying the batch listed above immediately.
  • Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

Full drug alert can be viewed here.

For stock control enquiries please contact Accord-UK Ltd Customer Services Team on 0800 373573.

For medical information enquiries please contact Accord-UK Ltd Medical Information Department on 01271 385257

 

Categories: National News
Syndicate content
Continuing Professional Development Just visiting this site means you are probably performing CPD - record it online at www.uptodate.org.uk
Site developed by Gary Warner
Drupal theme by Kiwi Themes.